Abstract
Background: Arrhythmia induced by etoposide is exceedingly rare. There are only a very few individual case histories of arrhythmias during etoposide infusion, including atrial fibrillation. Objective: Through this uncommon case, we propose to study the pathophysiology, the diagnosis and the management of this entity.
Case Report: We report a case of a 57-year-old man, without cardiac history, followed for endocrine tumor of the pancreas with liver metastases who had presented atrial fibrillation (AF) after etoposide infusion.
Conclusion: It is important to consider cardiac monitoring during etoposide infusion in patients with known cardiac disease or at high risk of cardiac complications.
Keywords: Atrial fibrillation, cardiotoxicity, chemotherapy, diagnosis, etoposide, prognosis.
Current Drug Safety
Title:An Exceptional Case of Atrial Fibrillation Arrhythmia Induced by Etoposide
Volume: 8 Issue: 4
Author(s): Wala Ben Kridis, Afef Khanfir, Faten Triki and Mounir Frikha
Affiliation:
Keywords: Atrial fibrillation, cardiotoxicity, chemotherapy, diagnosis, etoposide, prognosis.
Abstract: Background: Arrhythmia induced by etoposide is exceedingly rare. There are only a very few individual case histories of arrhythmias during etoposide infusion, including atrial fibrillation. Objective: Through this uncommon case, we propose to study the pathophysiology, the diagnosis and the management of this entity.
Case Report: We report a case of a 57-year-old man, without cardiac history, followed for endocrine tumor of the pancreas with liver metastases who had presented atrial fibrillation (AF) after etoposide infusion.
Conclusion: It is important to consider cardiac monitoring during etoposide infusion in patients with known cardiac disease or at high risk of cardiac complications.
Export Options
About this article
Cite this article as:
Kridis Ben Wala, Khanfir Afef, Triki Faten and Frikha Mounir, An Exceptional Case of Atrial Fibrillation Arrhythmia Induced by Etoposide, Current Drug Safety 2013; 8 (4) . https://dx.doi.org/10.2174/15748863113080990047
DOI https://dx.doi.org/10.2174/15748863113080990047 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Copper Chelation Chemistry and its Role in Copper Radiopharmaceuticals
Current Pharmaceutical Design Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials
Current Angiogenesis (Discontinued) The Place of Somatostatin Analogs in the Diagnosis and Treatment of the Neuoroendocrine Glands Tumors
Recent Patents on Anti-Cancer Drug Discovery Radionuclide Liver Cancer Therapies: From Concept to Current Clinical Status
Anti-Cancer Agents in Medicinal Chemistry Nitrogen-Containing Heterocycles as Anticancer Agents: An Overview
Anti-Cancer Agents in Medicinal Chemistry Nuclear Medicine: Proof of Principle for Targeted Drugs in Diagnosis and Therapy
Current Pharmaceutical Design Current Updates in the Medical Management of Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) PET Designated Flouride-18 Production and Chemistry
Current Topics in Medicinal Chemistry Functional Genome and Proteome Analyses of Cutaneous Autoimmune Diseases
Current Pharmaceutical Design Emerging Opportunities and Concerns for Drug Discovery at Serotonin 5-5-HT2B Receptors
Current Topics in Medicinal Chemistry The Development of Copper Radiopharmaceuticals for Imaging and Therapy
Medicinal Chemistry Anti-VEGF Anticancer Drugs: Mind the Hypertension
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Inhibitors of 11β-Hydroxylase (CYP11B1) for Treating Diseases Related to Excess Cortisol
Current Medicinal Chemistry Rare Pulmonary Tumors and Carcinoma Mimickers; Experience from an Interventional Radiology Unit with Radiologic-pathologic Correlation- A Pictoral Essay
Current Medical Imaging Preface: Additional Potential Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Antagonists
Current Pharmaceutical Design Clinical Evaluation of Anti-Obesity Drugs
Current Drug Targets Preface
Current Pharmaceutical Design Cellular Localisation of Chromogranins and Processed Products in the Diffuse Neuroendocrine System and Related Tumours
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Overview of the Primary Structure, Tissue-Distribution, and Functions of Tachykinins and their Receptors
Current Drug Targets Plastid Molecular Pharming II. Production of Biopharmaceuticals by Plastid Transformation
Mini-Reviews in Medicinal Chemistry